EdiGene, Inc
- Biotech or pharma, therapeutic R&D
EdiGene is a clinical-stage biotech company transforming gene-editing technologies into transformative cell and gene therapies for genetic disorders, cancer, and autoimmune diseases.
We have two advanced pipelines with clinical proof-of-concept: single gene KO real UCART within NHL and auto-immune disease POC (safety and efficacy, persistance comparable with autologous CAR-T) & gene-editing for treatment of DMD (safety and efficacy best in class).
The IND for these two pipeline is planned in 2025.
We are looking for a partner interested in our platform technology called MAGIC, a new single-gene editing target (global FTO) that resolve Both HvG and GvH in allogenic CAR-T (potential to expand in solid tumor target) , which drastically explore the real allogenic cell therapy.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}